Latest Share Buybacks News

Karoon Energy has successfully revived production at the Baúna SPS-92 well, lifting total output to 20,500 bopd and revising its 2026 capital expenditure guidance upward. Concurrently, the company plans a third phase of its on-market share buyback, citing undervaluation and disciplined capital allocation.

Third Age Health Services Limited lifted revenue by 18% to NZD 22.49 million in FY26, driven by acquisitions and aged care growth, while net profit after tax rose 25% to NZD 3.09 million.

Bankers Investment Trust reported a 3.7% NAV total return for the half-year to April 2026, outpacing the FTSE World Index, while declaring a 3.1% dividend increase. Fund manager Alex Crooke announced retirement, with Richard Clode set to take the helm.

Kingfish Limited posted a $13.6 million net loss for the year ended 31 March 2026, with portfolio returns lagging the benchmark amid geopolitical tensions and AI sector uncertainty.

Barramundi Limited’s May update reveals a 2.3% adjusted NAV decline, weighed down by CSL’s earnings downgrade and Brambles’ operational setbacks, despite positive contributions from Xero and Credit Corp.

InFocus Group Holdings is streamlining its software development operations by divesting Prodigy9 and consolidating under Onify, aiming for immediate cost savings and a leaner, AI-native delivery model.

Templeton Emerging Markets Investment Trust (TEMIT) posted a robust 41.3% net asset value total return for FY2026, outpacing its benchmark and narrowing its share price discount, while maintaining dividends and expanding share buybacks.

Australian Finance Group (ASX:AFG) has kicked off a $15 million on-market share buyback, aiming to return capital to shareholders while maintaining strategic flexibility amid recent share price softness.

ANZ Bank New Zealand has lodged an appeal against a High Court summary judgment in a class action related to consumer credit laws, prolonging legal uncertainty for the lender.

Infragreen launches a strategic review revealing a $10 million on-market buyback and potential asset sales to address significant undervaluation despite strong FY26 growth forecasts.

Neuren Pharmaceuticals reported a 15% rise in 2025 royalties from DAYBUE®, boosted by strong US sales and a new powder formulation launch. The company is progressing its pivotal Phase 3 trial for NNZ-2591 in Phelan-McDermid syndrome and reassessing capital management amid solid cash reserves.

Flight Centre Travel Group showcased robust growth and strategic innovation at its 2026 Investor Day, navigating geopolitical challenges with AI-driven efficiency and portfolio reshaping.